Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2107806 | 1.00 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2SLC6A4NPSR1PBRM1 | |
| SCHEMBL28263637 | 0.81 | MTNR1A (0.46) | SLC6A4PBRM1GAA | |
| SCHEMBL14402540 | 0.77 | ALDH1A1 (0.42) | ALDH1A1SLC6A4 | |
| SCHEMBL13265662 | 0.76 | ALDH1A1 (0.44) | ALDH1A1SLC6A4NPSR1PPARGPPARA | |
| SCHEMBL8854033 | 0.76 | ALDH1A1 (0.45) | ALDH1A1SLC6A4NPSR1PPARGPPARA | |
| SCHEMBL10042022 | 0.75 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2SLC6A4NPSR1PPARG | |
| SCHEMBL5754610 | 0.75 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2SLC6A4NPSR1PPARG | |
| SCHEMBL10572263 | 0.75 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2SLC6A4NPSR1PPARG | |
| SCHEMBL2106077 | 0.75 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2SLC6A4NPSR1PPARG | |
| SCHEMBL3439475 | 0.75 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2SLC6A4NPSR1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158667-B2 | Topical treatment of cataracts in dogs | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2012-04-17 | — | — | US | disclosed |
| US-20090082415-A1 | Topical treatment of cataracts in dogs | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082415-A1 | Topical treatment of cataracts in dogs | AKR1A1, AKR1B1, AKR1C1 | ALDH1A1 40/4885SMN1; SMN2 3195/4885SLC6A4 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.